Resistance to cisplatin (DDP) and dose-related toxicity remain two important obstacles in the treatment of prostate cancer (PCa) patients with DDP-based chemotherapy. We have investigated whether the knockdown of hypoxia-inducible factor-1 alpha (HIF-1α) by siRNA could enhance the antitumor activity of DDP, and aimed to determine the underlying mechanisms. Intravenous injection of attenuated Salmonella carrying a HIF-1α siRNA-expressing plasmid was used to knockdown HIF-1α in a PC-3 xenograft model. The in vitro and in vivo effects of HIF-1α siRNA treatment and/or DPP on PCa cell proliferation, apoptosis, glycolysis, and production of reactive oxygen species (ROS) were assessed by examining molecular markers specific to each process. The results demonstrated that the treatment of tumor-bearing mice with attenuated Salmonella carrying the HIF-1α siRNA plasmid greatly enhanced the antitumor effects of low-dose DDP. Further mechanistic studies demonstrated that knockdown of HIF-1α improved the response of PCa cells to DDP by redirecting aerobic glycolysis toward mitochondrial oxidative phosphorylation, leading to cell death through overproduction of ROS. Our findings indicate that DDP-based chemotherapy combined with targeting the HIF-1α-regulated cancer metabolism pathway might be an ideal strategy to treat PCa.
Results

HIF-1α was upregulated in PCa cell lines and primary human PCa cells. Western blot analyses were
performed to compare HIF-1α protein expression in four representative PCa cell lines (androgen-receptor-negative PC-3 and DU145, androgen-responsive LNCaP, and castration-resistant 22RV1) and in two non-malignant prostatic epithelial cell lines (RWPE-1 and BPH1). HIF-1α protein levels were markedly elevated in malignant cell lines compared to benign cell lines ( Fig. 1a ). Consistently, HIF-1α mRNA ( Fig. 1b ) was also upregulated in the PCa cell lines. Moreover, expression of vascular endothelial growth factor (VEGF) and glucose transporter type 4 (GLUT4), which are regulated by HIF-1α, were significantly increased as determined by quantitative real-time PCR (qRT-PCR, Fig. 1c,d ). Furthermore, HIF-1α transcriptional activity, measured using a reporter gene assay, was upregulated in the malignant cells compared to the benign cells ( Fig. 1e ). Moreover, immunohistochemical (IHC) analysis showed a significantly higher percentage of HIF-1α-positive cells in primary PCa tissue (61.26%) compared to normal tissue (9.44%), and HIF-1α expression was primarily localized in the nucleus (Fig. 1f ).
Next, we aimed to determine whether treatment with DDP and/or the si-HIF-1α plasmid could efficiently downregulate HIF-1α expression. Three PCa cell lines, PC-3, DU145, and LNCaP, were used to test the knockdown efficiency of HIF-1α expression following treatment with si-HIF-1α plasmid and/or DDP. The si-HIF-1α plasmid transfection alone significantly reduced HIF-1α protein expression in all three cell lines compared to the vehicle group ( Fig. 1g ), suggesting effective silencing of HIF-1α expression by the siRNA-expressing plasmid. DDP alone also slightly inhibited HIF-1α expression in PC-3, DU145, and LNCaP cells (Fig. 1g ). The combination of DDP and the si-HIF-1α plasmid inhibited HIF-1α protein expression even further, reaching inhibition of 87.4%, 89.6%, and 80.7% in PC-3, DU145, and LNCaP cells, respectively. Consistently, VEGF and GLUT4, which are both downstream of HIF-α, were also downregulated by DPP and si-HIF-1α alone, and the greatest reduction occurred when the cells were treated in combination with DDP and si-HIF-1α ( Fig. 1g ).
Combination of si-HIF-1α and DDP therapy markedly reduced cell viability, proliferation, and colony formation capability in PCa cell lines. MTT (Fig. 2a ) and EdU (Fig. 2b ,c) assays were both used to evaluate the effects of combination treatment on cell viability and cell proliferation in PC-3 and DU145 cells. The results showed that treatment with DDP, si-HIF-1α, and DDP/si-HIF-1α resulted in a significant reduction of cell viability and cell proliferation in PC-3 and DU145 cells 48 h after treatment, with a maximal reduction obtained by the DDP/si-HIF-1α treatment ( Fig. 2a-c) .
Colony assays reflected the capability of single cells to survive and proliferate under various treatment conditions. DDP or si-HIF-1α alone moderately but significantly inhibited colony formation, while the combination treatment dramatically decreased the colony formation capability of the cells (Fig. 2d ).
Combination treatment showed remarkable antitumor activity in a PCa xenograft model. PCa
xenografts were established through the subcutaneous injection of PC-3 cells on the right flank of male nude mice. Two weeks after the cell injection, tumor-bearing mice received treatments with DDP, si-HIF-1α, or DDP/ si-HIF-1α. The representative tumor xenograft for each treatment is shown in Fig. 3a . All treatments caused a significant inhibition of tumor expansion compared to the control, but the combination treatment with DDP and si-HIF-1α had the greatest antitumor effect. At sacrifice, the average tumor size of the control, DDP, si-HIF-1α, and combination groups were 1413 mm 3 , 932 mm 3 , 636 mm 3 , and 296 mm 3 , respectively (Fig. 3b ). Consistently, the average tumor weight in the DDP/si-HIF-1α group was significantly lower than those in the other groups (Fig. 3c ). The combination treatment also led to a significantly greater decrease of HIF-1α protein in the PCa xenograft compared to treatment with DDP or si-HIF-1α alone (Fig. 3d ).
Combination treatment with DDP and si-HIF-1α caused tumor cell apoptosis, but not cell cycle arrest in PCa xenografts. When examined by hematoxylin and eosin (H&E) staining, a number of necrotic foci and tissue disorganization were observed in the DDP, si-HIF-1α, and DDP/si-HIF-1α groups, with the combination group demonstrating the most serious injury (Fig. 4a ). The expression of proliferation cell nuclear antigen (PCNA), which is a marker for proliferation, was significantly reduced in groups treated with combination therapy, compared to other treatments (Fig. 4b ). The number of cells that stained positive for TUNEL, a marker of DNA fragmentation and apoptosis, increased significantly in the DDP, si-HIF-1α, and DDP/ si-HIF-1α groups compared to control (Fig. 4c ). The DDP/si-HIF-1α combination treatment caused the highest level of apoptosis. Consistent with this, Western blot analysis revealed an increase in markers of apoptosis in the DDP/si-HIF-1α group compared to the other groups, including an increase in the Bax/Bcl-2 ratio and the induction of caspase-3 and PARP cleavage ( Fig. 4d ,e). Differences in apoptosis and related protein changes were further confirmed by an in vitro study using PC-3 cells, which showed that DNA fragmentation, as well as the Bax/Bcl-2 ratio and induction of caspase-3 and PARP cleavage, were significantly increased in the DDP/si-HIF-1α group compared to the other groups ( Supplementary Figure 2a Another possible reason for the regression of the PC-3 xenografts with DDP/si-HIF-1α therapy may be due to cell cycle arrest. Therefore, the cell cycle distribution of xenografts was measured using flow cytometry. However, there was no significant change in the percentage of G1-phase cells in the xenograft treated with DDP alone, si-HIF-1α alone, or in combination ( Fig. 4f ). Consistently, the expression of cell cycle regulators such as p21, cyclin-dependent kinase 4 (CDK4), and specificity protein 1 (SP1) also had no significant change among all groups, as measured by Western blot analysis. These data suggest no significant change in cells arrested in the G1-phase ( Fig. 4g ).
DDP and/or HIF-1α siRNA induced apoptosis mediated by reactive oxygen species overproduc-
tion. Next, we tested whether HIF-1α downregulation sensitized PC-3 cells to apoptosis through overproduction of ROS. We examined the effect of the combined treatment with DDP and si-HIF-1α on levels of ROS with a dihydroethidium (DHE) assay. The combination treatment significantly enhanced DHE fluorescence intensity in PCa xenografts and PC-3 cells ( Fig. 5a and Supplementary Figure 3a , respectively). Further, the levels of cellular malondialdehyde (MDA) were higher in PCa xenografts and PC-3 cells following combination treatment ( Fig. 5b and Supplementary Figure 3b ). Moreover, the H 2 O 2 level was significantly increased in both the cytoplasm and culture medium of PC-3 cells after the combined treatment of DDP with si-HIF-1α ( Fig. 5c,d ). However, ROS production induced by combination treatment was markedly abolished by ROS scavengers, including N-acetyl cysteine (NAC) and dihydrolipoic acid (DHLA; Fig. 5c,d and Supplementary Figure 3a 
Overexpression of LDH-A partially blocked apoptosis induced by combined treatment with
DDP and HIF-1α siRNA. Glycolysis-related enzymes, such as hexokinase 2 (HK2), pyruvate kinase isozyme M2 (PKM2), phosphoinositide-dependent kinase 1 (PDK1), and lactate dehydrogenase A (LDH-A), are known to be regulated by HIF-1α. As expected, we found that LDH-A was significantly reduced at both the mRNA and protein levels following combination treatment in PCa xenografts (Fig. 6a,b ), as well as in PC-3 cells in vitro ( Supplementary Figure 4a,b) . Importantly, glucose uptake levels and lactate production are highly dependent on the rate of glycolysis. Decreased lactate production and glucose uptake were observed in PC-3 cells when treated with DDP/Si-HIF-1α, compared to other treatments ( Supplementary Figure 4c,d) .
LDH-A drives the switch of the metabolic pathway from mitochondrial oxidative phosphorylation to glycolysis. Thus, we tested whether overexpression of LDH-A could reduce DDP-triggered apoptosis. LDH-A overexpression reduced PARP and caspase-3 cleavage, as determined by Western blot (Fig. 6c ), and reduced histone-associated DNA fragmentation, as determined by ELISA ( Fig. 6d ), following combination treatment in PC-3 cells. The above data strongly suggests that HIF-1α-silencing enhances the sensitivity of PCa cells to DDP through a change in the preferential metabolic pathway from glycolysis to oxidative phosphorylation, leading to ROS production and subsequent induction of apoptosis. DDP/si-HIF-1α treatment caused little systemic toxicity in mice. We assessed systemic toxicity in mice caused by the treatment of DDP alone, si-HIF-1α alone, and in combination. There was no difference in body weight among the groups (Fig. 7a ). Histopathological examination by H&E staining showed that DDP/ si-HIF-1α treatment caused only minor toxicity to the tissues of the major internal organs (Fig. 7b ). There was no difference in hepatic function caused by combination therapy, as measured by serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT; Fig. 7c ). Moreover, no abnormalities such as appetite loss, fur ruffling, or behavioral changes were noticed following the combination treatment (data not shown).
Discussion
We tested our hypothesis that the sensitivity of PCa cells to DDP could be enhanced by reducing HIF-1α-regulated cancer metabolism. First, we demonstrated that downregulating HIF-1α through RNA interference could sensitize PCa xenografts and cell lines to DDP-induced apoptosis. Next, we investigated the underlying mechanisms of the enhanced sensitivity of cancer cells to DDP by HIF-1α downregulation, and found a switch of the metabolic pathway from glycolysis to oxidative phosphorylation, which caused an increase in ROS and sensitized the cells to DDP.
To overcome the resistance of the tumor to DDP and dose-related toxicity, efforts have been made to develop a combination strategy to improve the therapeutic effects of DDP. Recently, a combination of DDP and gene therapy aimed to improve antitumor efficacy has become appreciated 22-24, 26, 27 . For instance, it has been shown that when combined with adenovirus-mediated phosphatase and tensin homolog (PTEN), DDP has powerful antitumor activity in human small-cell lung cancer 28 . Also, NK4 gene therapy combined with low-dose DDP has been reported to be an effective regimen for oral squamous cell carcinoma 29 . Our previous study also demonstrated that DDP combined with gene therapy for both p53 and MDM2-siRNA greatly suppressed PCa and ovarian tumor growth in vitro and in vivo 22, 23 .
It has been well established that HIF-1α is upregulated in primary PCa and is important for invasion and migration in PCa [30] [31] [32] . Some patients with advanced PCa have high nuclear HIF-1α expression, which correlates with metastases at relapse, as well as reduced disease-specific survival 33 . We confirmed that HIF-1α was remarkably upregulated in human prostate tumors and PCa cell lines, but not in corresponding normal tissues or nonmalignant cells. Previous studies have also reported that HIF-1α is involved in promoting resistance of tumors to chemo-and radiotherapy 30 . This suggests that HIF-1α status might be a valid marker for predicting the sensitivity of cancers to chemotherapies. It has also been reported that DDP could downregulate HIF-1α by promoting HIF-1α degradation through the proteasome degradation pathway 15 . In our model, we found that HIF-1α was significantly decreased following combined treatment with DDP and si-HIF-1α, and the subsequent transcriptional activation of HIF-1α target genes, such as VEGF and GLUT4, was blocked. In this study, we also demonstrated for the first time that in vivo transfection of PC-3 xenografts with an HIF-1α-siRNA plasmid delivered by attenuated Salmonella Typhi Ty21a significantly improved the antitumor effects of DDP.
Next, we further explored the mechanism of the enhanced PCa sensitivity to DDP by downregulating HIF-1α in cell lines and xenografts. One possible mechanism of drug resistance is through the inactivation of apoptosis. Most anticancer therapies, including chemotherapy and radiotherapy, exert their efficacy by activating apoptosis signaling pathways in cancer cells. This study revealed that downregulation of HIF-1α using siRNA combined with DDP markedly increased apoptosis, as shown by multiple apoptosis markers such as cleaved caspase-3 and PARP. Another possible reason for the regression of PC-3 xenografts with DDP/si-HIF-1α therapy might be due to cell cycle arrest. To our surprise, combination therapy affects neither cell cycle distribution nor the expression of cell cycle regulators such as p21 and CDK4 in PC-3 xenografts. It has been proposed that HIF-1α is a major regulator of cell cycle arrest under hypoxic conditions 34 . Knockdown of HIF-1α can result in cell cycle disruption and alters the cellular response to chemotherapeutic drugs in a SP1-dependent manner 35 . Therefore, we analyzed the expression of SP1 and found no significant difference among all groups in our model. Taken together, these data suggested that the principal cause of enhanced tumor regression in the PC-3 xenografts following combination therapy depended on the induction of apoptosis, not the promotion of cell cycle arrest. However, the latter might still play a major role of tumor inhibition in other models 35, 36 .
Most chemotherapeutic agents, such as paclitaxel, doxorubicin, and cisplatin/DDP, could elicit mitochondrial permeabilization and intrinsic apoptosis by perturbing glycolysis. Increasing evidence has demonstrated a possible link between glycolysis and resistance to apoptosis in tumor maintenance and progression 37 . For example, HIF-1α engages the glycolysis pathway by inducing the expression of many glycolytic enzymes such as HK1 and LDH-A to inhibit apoptosis 15, 38 . Additionally, downregulation of HIF-1α improves the response of treatment-resistant cells and induces apoptosis through ROS production. It has been reported that oxidative conditions or increased levels of ROS downregulates HIF-1α expression, and decreased ROS levels upregulates HIF-1α expression 39, 40 . NAC or DHLA, as scavengers of ROS, have also been reported to stimulate HIF-1α expression 39, [41] [42] [43] , which is consistent with our findings in this study. A recent study showed that reduction of LDH-A, a direct target gene of HIF-1α, decreased cellular transformation and significantly increased apoptosis, as well as delayed tumor development and metastases, indicating that LDH-A is involved in tumor initiation and progression 44 . Consistent with the above studies, we also found that the key glycolytic enzyme LDH-A was significantly reduced following combined treatment with si-HIF-1α and DDP. Further mechanistic studies found that overexpression of LDH-A largely blocked apoptosis that was induced by the combination treatment. Taken together, by reducing the glycolytic enzyme LDH-A, combined treatment of si-HIF-1α and DDP induces apoptosis in PCa cells, leading to increased ROS production, and subsequently inhibiting tumor growth.
In summary, we showed that silencing HIF-1α greatly enhanced the therapeutic efficacy of low-dose DDP on PCa in a xenograft model. We further demonstrated that downregulation of HIF-1α overcame chemotherapy resistance in PCa by redirecting the metabolic pathway from aerobic glycolysis to mitochondrial oxidative phosphorylation. This work provides novel insights into the role of HIF-1α in drug resistance, and our results may help to develop new effective approaches to the treatment of patients with advanced PCa.
Methods and Materials
Ethics Statement. This study was carried out strictly following the recommendations in the Guide for the Care and Use of Laboratory Animals, Eighth Edition (Library of Congress Control Number: 2010940400, revised 2011). All experimental procedures for animal studies were approved by the Institutional Animal Care and Use Committee of the Shandong University affiliated Qianfoshan hospital (protocol number: S030). All appropriate means were undertaken to minimize suffering.
Normal and cancerous human prostate tissues. Both normal and malignant prostate tissue (Gleason score 9) were kindly provided by Inner Mongolia General Forestry Hospital (Yakeshi, China). Five samples of normal prostate tissue from benign areas of the prostatectomy specimens, and six samples of cancer tissues from radical prostatectomy specimens of patients with organ-confined tumors without previous therapy were used. Patients did not have other systemic diseases. The studies involving human specimens were approved by the Medical Ethics Committee of Inner Mongolia General Forestry Hospital Affiliated to Inner Mongolia University. Informed consent was obtained from each patient under an institutionally approved protocol. All methods were performed in accordance with the relevant guidelines and regulations of Inner Mongolia General Forestry Hospital Affiliated to Inner Mongolia University.
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Cell culture and treatment. The PCa cell lines PC-3, DU145, LNCaP, 22RV1, RWPE-1, and BPH1 were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) where they were characterized by mycoplasma detection, DNA-fingerprinting, isozyme detection, and cell vitality detection. They were cultured in Iscove's modified Dulbecco's medium (IMDM, Hyclone, Logan, UT, USA) supplemented with 10% (v/v) fetal bovine serum (FBS). The cells were treated with DDP (Sigma-Aldrich, St. Louis, MO) at 6 µg/ mL for 48 h, as previously reported 23 . The transfection reagent used was Lipofectamine 2000 (Invitrogen, CA, USA). Approximately 6 × 10 3 cells per well were transfected with the plasmids with or without DDP for 48 h, then cell viability was determined by (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich) assay following standard protocols as previously described 25 .
Construction of the si-HIF-1α plasmid and transfection of attenuated Salmonella Typhi
Ty21a. The construction of the si-HIF-1α plasmid is shown in Supplementary Figure 1 Xenograft model. Athymic male nude mice (nu/nu; 8 weeks old; the Institute of Zoology, Chinese Academy of Sciences, Beijing, China) were housed in standard microisolator conditions free of specific pathogens in accordance with the Animal Care and Use protocol approved by Shandong university. These mice were used to establish a xenograft model. The PC-3 suspension (2 × 10 6 cells in 100 µL PBS per mouse) was subcutaneously injected into the right flank of the animals. The tumor sizes were measured from the first day until 40 days post-cell injection, using calipers and the formula: V (volume) = LW 2 × 0.52, where "L" represents the greatest length and "W" represents the perpendicular width. After tumors reached approximately 150-200 mm 3 (~2 weeks), the animals were randomized into four groups (n = 6/group): normal control group, with an intraperitoneal injection (i.p.) of normal saline; DDP group, with i.p. injection of DDP; si-HIF-1α group, with transfection of si-HIF-1α; and DDP/si-HIF-1α group, with combined treatment of si-HIF-1α and DDP. The bacteria, carrying the si-HIF-1α plasmid at 1 × 10 7 CFU/100 µL, were injected through the tail vein at day 14 and day 28 post-PC-3 cell inoculation as previously described 18, 22 . After the first bacterial injection, DDP was administered (2.0 mg/kg, i.p.) twice a week for 2 weeks as previously described 23, 24 .
Western blot assay. Western blotting was performed as previously described 22, 23, 46 . The lysates from the xenografts or cell lines with different treatments were homogenized in RIPA lysis buffer using a homogenizer. The supernatants were collected by centrifugation (12, TUNEL and EdU labeling assays. Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) staining was performed as previously reported 23 . Briefly, the xenografts from each treatment were fixed in buffered neutral 10% formalin, dehydrated in a series of graded alcohol, embedded in paraffin, and sectioned (5 μm). Deparaffinized and rehydrated slides were used for TUNEL staining following the manufacturer's instructions (Promega, Madison, WI, USA). Apoptosis of cells was quantitatively analyzed by counting TUNEL-positive cells from 10 randomly selected fields in three slides per mouse, from at least five mice in each group. 5-ethynyl-2′-deoxyuridine (EdU) was detected with Click-iT ® EdU Alexa Fluor ® 647 Imaging Kit (C10640, Invitrogen, Carlsbad, CA). Imaging was performed on a fluorescent microscope (Nikon, Melville, NY, USA) and the signals were quantified by ImageJ software. ROS measurement. PC-3 xenograft tissues were immediately frozen in optimal cutting temperature (OCT) compound and frozen sections (10 µm) were prepared at −20 °C using a cryostat (Leica, Electronic). The sections were thawed at room temperature for 30 min and then incubated in dihydrogen ethidium (10 μM; DHE, Sigma-Aldrich) for 30 min at 37 °C in the dark. Next, the sections were washed three times and incubated with DAPI (2 µg/mL). Digital images were captured by a fluorescent microscope (Nikon), and the fluorescence intensity, normalized to that of the control, was quantified using ImageJ software.
Following treatment, PC-3 cells (1.0 × 10 5 cells/well) cultured on six-well plates were incubated with DHE dye (5 μm/mL) diluted in Hank's balanced salt solution (HBSS) for 30 min at 37 °C in the dark. Images were captured on a fluorescence microscope and ROS signals were quantified using ImageJ software. The H 2 O 2 concentrations were measured using an H 2 O 2 assay kit (Beyotime, Beijing, China) according to the manufacturer's instructions.
Colony formation analysis.
Colony formation assays were performed as previously described 22, 23 . Briefly, cells were seeded in six-well plates (500 cells/well) and cultured for 14 days. Colonies were fixed with 10% formaldehyde for 15 minutes, and stained with 0.5% crystal violet for 30 minutes. The cells were then photographed and counted.
